Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

Inclusion Criteria: * Healthy male and female subjects. * Age between 18 and 40 years (both included). * Anxiety questionnaire PAF (pre-selection of subjects) - values above T\> 60 are regarded as conclusive. * Inconclusive case history and diagnosis. * Subject must be capable of giving informed consent. * Acceptance of written consent to participate in the study after education in written and oral form (informed consent). Exclusion Criteria: * Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination. * Clinically relevant pathological findings from clinical and laboratory findings. * Presence of clinically relevant pathological EEG features or artifact-free portion of the screening EEG \<30%. * Clinically relevant allergic symptoms. * Detection of alcohol at the time of initial examination (day SC) or on study day A (positive alcohol test) or by case history. * Detection of drugs (positive drug test) at the time of initial examination (day SC). * Consumption of clinically relevant medication during last fourteen days before and during the active study period based on the notification of the subject or his case history. * Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensives). * Known intolerance / hypersensitivity (allergy) to plant derived extracts (Passion flower dry extract) or any of the ingredients of the investigational product (anamnestic). * Presence of a rare, genetic disease such as fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase deficiency (anamnestic). * BMI (Body Mass Index) \<18 or\> 32. * Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day) or tobacco (more than 20 cigarettes per day). * Smoking on day of A.